Steve Bryson, PhD, science writer —

Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.

Articles by Steve Bryson

Review: Ocrevus best of 4 antibody therapies for progressive MS

Among four antibody-based therapies for multiple sclerosis (MS), Ocrevus (ocrelizumab) works best to prevent disability progression and other measures of disease activity in people with PPMS, or primary progressive MS, a review study found. However, the medication is associated with an increased risk of infection, data suggested.

GlobeStar, AIP team up to design clinical trials for Project Amethyst

GlobeStar Therapeutics (GSTC) is teaming up with Advanced Innovative Partners (AIP) to design and implement clinical trials of Project Amethyst, an investigational therapy for multiple sclerosis (MS) that aims to reduce neurodegeneration — when nerve cells in the body lose function and ultimately die. The new memorandum of understanding (MOU)…

T-cell changes reflect pregnancy’s protective effects in MS

Changes in the gene activity within immune T-cells explain why women with multiple sclerosis (MS) improve during pregnancy, a study reports. Gene activity changes during and after pregnancy were highly similar between MS patients and healthy women. Many of the genes whose activity was altered during pregnancy were associated…

Blood-clotting protein triggers brain inflammation in MS: Study

A blood-clotting protein called fibrin can activate immune cells in the brain and contribute to inflammation and neurodegeneration in multiple sclerosis (MS), a study revealed. Because blood vessels become leaky in neurodegenerative conditions like MS, the blood can cross into the brain, which is known to activate multiple pro-inflammatory…

Periods of oxygen deprivation improve symptoms of MS in mice

A non-invasive treatment called acute intermittent hypoxia, or AIH, involving periods of oxygen deprivation, was found to ease signs and symptoms of progressive multiple sclerosis (MS) in a mouse model of the disease. Given during the peak of disease activity, AIH treatment — basically, periods of reduced oxygen exposure…

Nanocapsules with retinoic acid may treat MS inflammation: Study

Modified nanocapsules containing retinoic acid can suppress inflammation and prompt the growth of cells that produce nerve fibers’ myelin coating, which is lost in multiple sclerosis (MS), a cell-based study shows. The results demonstrated how lipid (fat) nanocapsules that contain medicines can access the brain and treat the two…

Researchers uncover key biological pathway for MS

Interleukin-3 (IL-3), an inflammatory signaling protein, seems to coordinate the recruitment of immune cells from the blood into the brain, leading to worsening inflammation and symptoms related to multiple sclerosis (MS), a study revealed. Targeting IL-3-mediated communication may be an effective therapeutic strategy for MS and other brain disorders,…

Itaconate, a common metabolite, shows promise in MS mouse model

Itaconate, a metabolite produced during cellular energy production activities, was found to restore the balance of immune T cells and reduce multiple sclerosis (MS) symptoms in a mouse model of the disease, a study reported. The common metabolite specifically suppressed the production of pro-inflammatory T cells while promoting the…

Energy metabolite has potential to treat MS, autoimmune conditions

Supplementation with phosphoenolpyruvate (PEP), a molecule produced during cellular energy generation, eased the signs and symptoms of multiple sclerosis (MS) in a mouse model of the disease, a study revealed. The metabolite inhibited a protein called JunB, which blocked the production of the pro-inflammatory molecule interleukin-17 (IL-17) and suppressed…

Mayzent, vitamin D combo alleviates MS signs in mouse study

Using Mayzent (siponimod) and vitamin D3 as a combination therapy was found to improve motor function and promote remyelination — restoring the damaged myelin sheath around nerve fibers —  in a mouse model of multiple sclerosis (MS). “Our results demonstrate for the first time the potential synergistic effects…

MS Cognitive Problems Can Ease With Rehab, Mindfulness Training

Two alternative treatments for the cognitive challenges people with multiple sclerosis (MS) can face in daily life — cognitive rehabilitation therapy (CRT) and mindfulness-based cognitive therapy (MBCT) — were found to helpful in a clinical trial. Patients randomized to either treatment approach in the REMIND-MS study had fewer…

Use of Virtual Reality Physiotherapy in MS Found to Boost Adherence

Uses of virtual reality-based physiotherapy to improve balance and gait in people with multiple sclerosis (MS) are linked to lower dropout rates than those found with conventional rehabilitation methods, a review of clinical trials suggested. Although the difference between the two physiotherapy approaches was not statistically significant, adherence to…

Alcohol Consumption Is No Protection From MS: UK Study

The risk of developing multiple sclerosis (MS) doesn’t seem to be influenced by consuming alcohol, according to a large-scale analysis in the U.K. After adjusting for known MS risk factors, including smoking, childhood obesity, socioeconomic status, or genetics, the findings remained the same. The analysis was published in Nature…

Stem Cell Transplant More Effective for SPMS Than Medications: Study

A stem cell transplant more effectively slowed disability worsening in people with active secondary progressive multiple sclerosis (SPMS) than anti-inflammatory treatments and disease-modifying therapies (DMTs), a study has found. More transplant recipients also experienced clinical improvements that were sustained after three and five years. After 10 years,…

Myelin Provides Metabolic Support to Inhibitory Brain Cells: Study

Myelin, the fatty-rich material surrounding nerve fibers that’s progressively damaged in multiple sclerosis (MS), provides metabolic support to a type of nerve cell in the brain that controls the activity of other nerve cells, a study discovered. Researchers showed mitochondria, the cell’s energy producers, are specifically clustered in…

Lcn-2 Protein Marks Intestinal Inflammation in MS, Study Shows

People with relapsing-remitting multiple sclerosis (RRMS) have elevated levels of the lipocalin 2 (Lcn-2) protein in their stool samples, a marker for intestinal inflammation, compared with healthy controls, a study demonstrated. Among patients, findings also demonstrated those with high fecal Lcn-2 had changes in their gut microbiome, the collection…

RRMS Transition to SPMS Fell With Start of DMTs, Swedish Study Finds

The risk of transitioning from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive multiple sclerosis (SPMS) declined significantly after the introduction of disease-modifying therapies (DMT), according to a large nationwide Swedish study. Data showed that SPMS conversion risk rose by 3% each year before the first generation of…